LDP-02: Phase I/II

In a 29-patient Phase I/II trial, single subcutaneous or intravenous doses of LDP-02 were well tolerated and blocked integrin alpha(4)beta(7) receptors on circulating lymphocytes for several weeks. Patients in the trial also received standard therapy. Complete clinical and endoscopic remission was seen in 2 patients receiving 0.5 mg/kg LDP-02 intravenously. Data were presented at the Digestive Disease Week meeting in San Diego. ...